Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

SEATTLE, May 19, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it is advancing two of its product candidates from its PharmacoSurgery™ platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs. Both of these product candidates are added to standard irrigation solutions and delivered intra-operatively to the operative site throughout the surgical procedure to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery.

"I am pleased to report today that we have already begun advancing Phase 3 clinical programs for OMS103HP and OMS302," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "Both of these drugs generated positive efficacy and safety data in large Phase 2 clinical trials and, based on our analysis of those data, we are optimistic that each drug's clinical benefits will be further demonstrated in its respective Phase 3 clinical program."

The OMS103HP Phase 3 clinical program will evaluate the drug's safety and efficacy in improving postoperative joint function and reducing pain following arthroscopic partial meniscectomy surgery. The program will consist of two randomized, double-blind, vehicle-controlled, multicenter trials to be conducted in North America and Europe. Omeros expects data from the North American trial in the first half of 2012. The Company is in discussions with European regulatory authorities regarding the second clinical trial and, assuming sufficient resources, plans to begin that trial during the fourth quarter of 2011. The primary endpoint for these trials will be performance on the Knee Injury and Osteoarthritis Outcome Score (KOOS), a validated patient-reported o
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... PRINCETON, N.J., Jan. 4, 2011 Pharmasset, Inc. (Nasdaq: ... 29th Annual J.P. Morgan Healthcare Conference to be held January ... CA. Schaefer Price, President and Chief Executive Officer, will provide ... at 9:00 AM (PT). To access a simultaneous ...
... Jan. 4, 2011 Boston Scientific Corporation (NYSE: ... M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article ... the American Medical Association .  The article reported on a ... received an implantable cardioverter defibrillator (ICD) did not meet evidence-based ...
Cached Medicine Technology:Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 3Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article 2
(Date:4/18/2014)... 2014) -- A group of scientists from the ... Sanders-Brown Center on Aging has found interesting new ... function in Parkinson,s disease (PD). , Published ... study, which assessed cognitive function in depressed and ... replacement therapy commonly used to treat motor symptoms ...
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... ... California, which provides health coverage to over 3 million Southern California residents, announced today ... to selected members who are struggling to lose weight. , , ... (PRWEB) April 12, 2010 -- ...
... ... of Tampa, FL has announced the formation of a charitable organization to benefit people of ... Odom,s team will include Tampa urologist Howard Heidenberg, a specialist in male fertility issues, ... ...
... ... we all need it. Unfortunately, for many, it seems that life just gets in the way; ... For 27 year old Helen Smailes from Keighley in the UK these were just some of ... she is happier and healthier than ever. , ...
... analysis has found that a considerable proportion of ... benefit from palliative radiation therapy (radiotherapy) despite spending ... early online in CANCER , a peer-reviewed ... indicates that greater efforts are needed to tailor ...
... SUNDAY, April 11 (HealthDay News) -- It,s easy to help your ... to the Alliance for a Healthier Generation. , For starters, join ... And you can share the fun and health benefits, too. ... to get on their bicycles, roller skates or blades and scooters. ...
... Khanna ... April 25. , ... 10, 2010 -- The Khanna institute to attend the YHC Health Expo on April 25th ... , , ,Khanna Institute of LASIK & Refractive surgery, an eye surgery center that caters ...
Cached Medicine News:Health News:Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients 2Health News:Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients 3Health News:Tampa Civil Attorney Gene Odom Announces Fertility Charity Partnership with Board Certified Male and Female Fertility Specialists 2Health News:Online Body Transformation Contest Proven to be a Life Changer 2Health News:Online Body Transformation Contest Proven to be a Life Changer 3Health News:Terminal cancer patients do not receive appropriate radiation therapy 2Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 2Health News:Khanna Institute of Vision and Your Health Connection Spring Expo 3
... provides fingertip ratchet disengagement allowing smooth, ratchet-free ... offers state-of-the-art quality in an instrument of ... durability. Low profile cutting tips allow access ... I instruments are available in just about ...
... The patented ratchet design provides fingertip ... ,The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ...
... of procedurally specific tip configurations provide ... access to all areas of the ... Handled Graspers feature an infinite position ... without tearing or slipping even ...
Smith & Nephew ACUFEX scissors are constructed without pins for maximum strength, dependability, durability, and safety.,A wide range of tips and angles enable the surgeon to effectively dissect any ...
Medicine Products: